Animal Feed · Founded 2010 · www.mukkaproteins.com · BSE 544135 · NSE MUKKA · ISIN INE0CG401037
No Notes Added Yet
Business
Mukka Proteins Ltd. is an Indian manufacturer and supplier of fish protein products. The company's core business involves processing fish into high-quality fish meal, fish oil, and allied products like fish soluble paste. These products serve as essential ingredients in the animal feed industry, primarily for aquaculture (aquafeed), poultry feed, and pet food manufacturers. The company's business model revolves around sourcing fresh fish, processing it in its facilities, and selling the derived protein products to both domestic and international customers.
Revenue Mix
Mukka Proteins' revenue is primarily generated from the sale of:
Fish Meal: Used as a protein-rich ingredient in aquafeed, poultry feed, and other animal feeds.
Fish Oil: Utilized for its Omega-3 fatty acid content in aquafeed, pharmaceutical, and nutraceutical industries, as well as in pet food.
Allied Products: Includes fish soluble paste and other by-products from the fish processing.
While specific percentage contributions are not consistently disclosed publicly post-listing, these three categories represent the entirety of their product offerings.
Industry
The company operates within the global animal feed industry, specifically focusing on marine-derived protein ingredients. This industry is driven by the demand for high-quality protein in animal nutrition. Mukka Proteins is positioned as one of India's leading manufacturers and exporters of fish meal and fish oil. It competes with other domestic and international players, differentiating itself through established supply chains, processing capabilities, and customer relationships across various geographies including Asia and the Middle East.
MOAT
Mukka Proteins possesses several advantages:
Scale and Integrated Operations: Significant manufacturing capacity in India and a degree of integration in its sourcing and processing operations can lead to cost efficiencies.
Established Supply Chain & Logistics: Long-standing relationships with fish suppliers and a robust distribution network for raw materials and finished products.
Customer Relationships: A diversified customer base with long-term relationships with domestic and international aquafeed, poultry feed, and pet food manufacturers.
Export Focus: A significant portion of its revenue comes from exports, diversifying its market exposure and reducing reliance on the domestic market alone.
Growth Drivers
Key factors that can drive growth for Mukka Proteins include:
Rising Global Protein Demand: Increasing global population and disposable incomes are expected to drive higher consumption of animal protein (fish, poultry), subsequently boosting demand for animal feed ingredients.
Growth in Aquaculture: The aquaculture sector continues to expand globally as a sustainable source of protein, directly increasing the need for fish meal and fish oil.
Expansion into New Markets/Products: Potential to expand into new geographical markets or further diversify its product offerings within the pet food or human nutraceutical segments.
Capacity Utilization & Efficiency: Optimizing existing capacity and potential future capacity expansions to meet growing demand.
Risks
Raw Material Price Volatility: Fluctuations in the availability and prices of fish (sardines, anchovies, etc.) due to environmental factors, fishing quotas, or seasonality can impact profitability.
Regulatory & Environmental Risks: Changes in fishing regulations, environmental protection laws, and import/export policies in key markets could affect operations.
Disease Outbreaks: Outbreaks of diseases in aquaculture or poultry can reduce demand for animal feed.
Competition: Intense competition from other fish meal and fish oil manufacturers, as well as alternative protein sources (e.g., soy protein, insect meal).
Foreign Exchange Fluctuations: As a significant exporter and importer, the company is exposed to currency exchange rate risks.
Management & Ownership
Mukka Proteins is promoted by Kalandan Mohammed Haris, Kalandan Mohammed Arif, and Kalandan Mohammed Althaf, who are actively involved in the company's operations and have extensive experience in the marine products industry. The company is family-led, with the promoter group holding a significant stake in the company post its public listing. This indicates a strong alignment of interests between management and shareholders.
Outlook
Mukka Proteins operates in a structurally growing industry driven by increasing global protein consumption. The company's established position as a key manufacturer and exporter of marine-derived protein ingredients for animal feed positions it to benefit from the expansion of the aquaculture and poultry sectors. However, the business is susceptible to commodity price volatility for its raw materials, regulatory changes concerning fishing and environmental norms, and intense competition from both marine and alternative protein sources. Its ability to navigate these challenges while capitalizing on rising global demand for feed ingredients will be crucial for sustained performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 257 | 172 | 149 | 303 | 382 | 171 | 245 | 653 | 381 | 490 |
| Other Income | 3 | 3 | 3 | 6 | 4 | 3 | 6 | 5 | 15 | 2 |
| Total Income | 260 | 175 | 152 | 309 | 386 | 173 | 251 | 658 | 396 | 491 |
| Total Expenditure | 225 | 158 | 140 | 262 | 352 | 156 | 224 | 608 | 347 | 442 |
| Operating Profit | 35 | 17 | 13 | 47 | 33 | 17 | 27 | 50 | 49 | 50 |
| Interest | 7 | 8 | 9 | 11 | 10 | 11 | 13 | 15 | 15 | 16 |
| Depreciation | 3 | 3 | 4 | 4 | 3 | 3 | 4 | 4 | 5 | 5 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 26 | 6 | 0 | 32 | 20 | 3 | 10 | 32 | 29 | 28 |
| Provision for Tax | -2 | 0 | -0 | 6 | 6 | 1 | 2 | 7 | 8 | 9 |
| Profit After Tax | 28 | 5 | 1 | 26 | 14 | 2 | 7 | 24 | 21 | 20 |
| Adjustments | -1 | -1 | 1 | -0 | -1 | -1 | -1 | -1 | -1 | -1 |
| Profit After Adjustments | 27 | 4 | 2 | 26 | 14 | 2 | 6 | 24 | 21 | 19 |
| Adjusted Earnings Per Share | 0.9 | 0.1 | 0.1 | 0.9 | 0.5 | 0.1 | 0.2 | 0.8 | 0.7 | 0.6 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 409 | 549 | 604 | 771 | 1177 | 1380 | 1006 | 1449 | 1769 |
| Other Income | 3 | 8 | 10 | 7 | 7 | 17 | 15 | 29 | 28 |
| Total Income | 412 | 557 | 614 | 778 | 1184 | 1397 | 1022 | 1478 | 1796 |
| Total Expenditure | 385 | 525 | 582 | 724 | 1091 | 1274 | 912 | 1335 | 1621 |
| Operating Profit | 26 | 32 | 32 | 54 | 93 | 123 | 110 | 143 | 176 |
| Interest | 4 | 7 | 8 | 10 | 16 | 26 | 37 | 54 | 59 |
| Depreciation | 2 | 5 | 8 | 9 | 12 | 12 | 14 | 17 | 18 |
| Exceptional Income / Expenses | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 19 | 20 | 15 | 36 | 66 | 87 | 60 | 75 | 99 |
| Provision for Tax | 5 | 6 | 4 | 10 | 18 | 13 | 12 | 18 | 26 |
| Profit After Tax | 14 | 14 | 11 | 26 | 48 | 74 | 48 | 57 | 72 |
| Adjustments | 1 | -0 | -2 | -2 | -3 | -4 | -2 | -5 | -4 |
| Profit After Adjustments | 14 | 13 | 9 | 24 | 44 | 70 | 46 | 52 | 70 |
| Adjusted Earnings Per Share | 0.6 | 0.6 | 0.4 | 1.1 | 2 | 2.3 | 1.5 | 1.7 | 2.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 44% | 7% | 19% | 0% |
| Operating Profit CAGR | 30% | 15% | 35% | 0% |
| PAT CAGR | 19% | 6% | 39% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -4% | NA% | NA% | NA% |
| ROE Average | 12% | 17% | 24% | 25% |
| ROCE Average | 12% | 14% | 17% | 17% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 44 | 57 | 67 | 98 | 148 | 396 | 441 | 499 |
| Minority's Interest | 0 | 1 | 3 | 5 | 8 | 12 | 16 | 30 |
| Borrowings | 16 | 14 | 9 | 9 | 5 | 6 | 3 | 32 |
| Other Non-Current Liabilities | 3 | 4 | 4 | 6 | 11 | 5 | 7 | 11 |
| Total Current Liabilities | 137 | 217 | 272 | 274 | 403 | 521 | 610 | 1049 |
| Total Liabilities | 201 | 293 | 355 | 392 | 575 | 941 | 1076 | 1621 |
| Fixed Assets | 48 | 77 | 78 | 81 | 83 | 84 | 93 | 193 |
| Other Non-Current Assets | 11 | 10 | 20 | 25 | 28 | 41 | 58 | 139 |
| Total Current Assets | 142 | 206 | 257 | 286 | 464 | 817 | 926 | 1289 |
| Total Assets | 201 | 293 | 355 | 392 | 575 | 941 | 1076 | 1621 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 10 | 1 | 1 | 3 | 12 | 27 | 94 | 3 |
| Cash Flow from Operating Activities | -20 | -25 | 2 | 5 | -56 | -150 | -112 | -111 |
| Cash Flow from Investing Activities | -23 | -28 | -14 | -11 | -3 | -48 | -35 | -146 |
| Cash Flow from Financing Activities | 34 | 54 | 13 | 15 | 75 | 266 | 56 | 267 |
| Net Cash Inflow / Outflow | -9 | 1 | 2 | 8 | 15 | 68 | -91 | 10 |
| Closing Cash & Cash Equivalent | 1 | 2 | 3 | 12 | 27 | 94 | 3 | 13 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.65 | 0.6 | 0.41 | 1.1 | 2 | 2.34 | 1.55 | 1.74 |
| CEPS(Rs) | 0.73 | 0.83 | 0.88 | 1.56 | 2.7 | 2.89 | 2.05 | 2.46 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 2 | 2.57 | 3.02 | 4.47 | 6.72 | 13.2 | 14.69 | 16.64 |
| Core EBITDA Margin(%) | 5.71 | 4.33 | 3.62 | 6.07 | 7.11 | 7.49 | 9.25 | 7.74 |
| EBIT Margin(%) | 5.66 | 4.9 | 3.89 | 5.93 | 6.8 | 8.06 | 9.5 | 8.7 |
| Pre Tax Margin(%) | 4.6 | 3.59 | 2.56 | 4.67 | 5.44 | 6.21 | 5.87 | 5.08 |
| PAT Margin (%) | 3.35 | 2.47 | 1.82 | 3.35 | 3.92 | 5.28 | 4.69 | 3.86 |
| Cash Profit Margin (%) | 3.94 | 3.33 | 3.21 | 4.46 | 4.9 | 6.16 | 6.01 | 4.98 |
| ROA(%) | 6.81 | 5.5 | 3.4 | 6.91 | 9.82 | 9.8 | 4.77 | 4.23 |
| ROE(%) | 31.1 | 27 | 17.89 | 31.32 | 38.61 | 27.32 | 11.5 | 12.15 |
| ROCE(%) | 18.24 | 16.57 | 11.08 | 18.35 | 24.44 | 19.54 | 11.82 | 11.93 |
| Receivable days | 25.44 | 21.1 | 25.05 | 25.87 | 26.3 | 38.72 | 68.51 | 47.06 |
| Inventory Days | 80.39 | 68.16 | 80.08 | 74.55 | 59.45 | 84.67 | 175.65 | 175.18 |
| Payable days | 62.95 | 54.51 | 64.49 | 56.82 | 44.27 | 42.92 | 65.49 | 59.68 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 15.62 | 21.12 | 10.6 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 2.76 | 2.23 | 1.11 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.21 | 0.26 | 0.27 | 0.24 | 0.21 | 0.96 | 1.38 | 0.87 |
| EV/Core EBITDA(x) | 3.33 | 4.6 | 5.04 | 3.35 | 2.67 | 10.84 | 12.63 | 8.79 |
| Net Sales Growth(%) | 0 | 34.36 | 9.94 | 27.6 | 52.77 | 17.22 | -27.06 | 44.02 |
| EBIT Growth(%) | 0 | 16.41 | -12.85 | 94.49 | 80.51 | 37.59 | -14.01 | 32.02 |
| PAT Growth(%) | 0 | -0.78 | -18.89 | 134.5 | 84.07 | 56.35 | -35.27 | 18.69 |
| EPS Growth(%) | 0 | -7.8 | -31.88 | 169.71 | 82.06 | 16.56 | -33.68 | 12.06 |
| Debt/Equity(x) | 1.88 | 2.51 | 2.39 | 1.76 | 1.72 | 0.91 | 1.02 | 1.54 |
| Current Ratio(x) | 1.04 | 0.95 | 0.95 | 1.05 | 1.15 | 1.57 | 1.52 | 1.23 |
| Quick Ratio(x) | 0.38 | 0.42 | 0.39 | 0.44 | 0.58 | 0.75 | 0.59 | 0.41 |
| Interest Cover(x) | 5.33 | 3.74 | 2.93 | 4.72 | 5 | 4.37 | 2.62 | 2.4 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0.33 | 0.46 | 1.39 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 |
| FII | 6.46 | 5.08 | 2.82 | 2.63 | 2.63 | 2.08 | 1.7 | 1.7 | 1.7 | 1.73 |
| DII | 2 | 2.5 | 2 | 1.98 | 1.98 | 1.87 | 1.66 | 0.17 | 0 | 0 |
| Public | 18.2 | 19.09 | 21.85 | 22.06 | 22.05 | 22.71 | 23.31 | 24.8 | 24.97 | 24.93 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| FII | 1.94 | 1.52 | 0.84 | 0.79 | 0.79 | 0.62 | 0.51 | 0.51 | 0.51 | 0.52 |
| DII | 0.6 | 0.75 | 0.6 | 0.6 | 0.6 | 0.56 | 0.5 | 0.05 | 0 | 0 |
| Public | 5.46 | 5.73 | 6.55 | 6.62 | 6.62 | 6.81 | 6.99 | 7.44 | 7.49 | 7.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +44% | +7% | +19% | — |
| Operating Profit CAGR | +30% | +15% | +35% | — |
| PAT CAGR | +19% | +6% | +39% | — |
| Share Price CAGR | -4% | — | — | — |
| ROE Average | +12% | +17% | +24% | +25% |
| ROCE Average | +12% | +14% | +17% | +17% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 | 73.33 |
| FII | 6.46 | 5.08 | 2.82 | 2.63 | 2.63 | 2.08 | 1.7 | 1.7 | 1.7 | 1.73 |
| DII | 2 | 2.5 | 2 | 1.98 | 1.98 | 1.87 | 1.66 | 0.17 | 0 | 0 |
| Public | 18.2 | 19.09 | 21.85 | 22.06 | 22.05 | 22.71 | 23.31 | 24.8 | 24.97 | 24.93 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| FII | 1.94 | 1.52 | 0.84 | 0.79 | 0.79 | 0.62 | 0.51 | 0.51 | 0.51 | 0.52 |
| DII | 0.6 | 0.75 | 0.6 | 0.6 | 0.6 | 0.56 | 0.5 | 0.05 | 0 | 0 |
| Public | 5.46 | 5.73 | 6.55 | 6.62 | 6.62 | 6.81 | 6.99 | 7.44 | 7.49 | 7.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.